Oxford’s two full-dose regimes of its COVID-19 vaccine candidate showed better immune response compared to a full-dose followed by a half-dose booster, said the university, quoting data from new phase I/II clinical trials.
The interim late-stage trials of the vaccine, however, had recently shown a higher efficacy when a half dose was followed by a full dose, compared to a two full-dose regime, though more work needs to be done to affirm the result.
The details from the recent phase I/II clinical trials, however, made no reference to the half-dose/full-dose regime, which Oxford has said had been unplanned, but approved by regulators.
The university said it had explored two dosing regimes in early-stage trials, a full-dose/full-dose regime and a full-dose/half-dose regime, investigated as a possible “dose sparing” strategy.
“The booster doses of the vaccine are both shown to induce stronger antibody responses than a single dose, the standard dose/standard dose inducing the best response,” the university said in a statement.
The vaccine stimulates broad antibody and T cell functions, it said after publishing further data from the phase I/II clinical trials.